RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Filing todayAgree with your point on Soleus. They were made aware and bought in. So they were at least consulted around the offer and we can only hope they are more forceful in either outcome with the clinical trial. If it is a dud --keep cutting costs, building cash and use a modest dividend policy to start building back value for shareholders. If successful, push them for the best route to capitalize on it and if they need more time for partner discussions, provide a bridge to get there so they get a good deal. We know they need the help in cutting financial deals. Soleus can't be too happy with what they've seen and the hole in the portfolio. I've seen their perf and they were up single digits for the year, which in their universe isn't that bad.